Clinical Trial Update: Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating adjuvant nivolumab after salvage resection in head and neck cancer patients previously treated with definitive therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Trisha Wise-Draper | Conditions: Head and Neck Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING